Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020)
Pulmonx (LUNG) reported Preferred Stock Liabilities of $207.6 million for Q3 2020, up 1.1% year-over-year from $205.3 million in Q4 2019, and little changed on a QoQ basis from $207.6 million in Q2 2020.
Pulmonx (LUNG) has 2 years of Preferred Stock Liabilities data on file, last reported at $207.6 million in Q3 2020.
- Quarterly Preferred Stock Liabilities rose 1.1% year-over-year to $207.6 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $207.6 million (up 1.1% YoY) and the FY2019 annual result came in at $205.3 million, up 46.11% from the prior year.
- Preferred Stock Liabilities held at $207.6 million in Q3 2020 per LUNG's latest filing, from $207.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $207.6 million in Q1 2020 and bottomed at $205.3 million in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Pulmonx | 67.30 Mn | -2.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 207.60 Mn |
| Jun 30, 2020 | 207.60 Mn |
| Mar 31, 2020 | 207.60 Mn |
| Dec 31, 2019 | 205.34 Mn |
| Sep 30, 2019 | 205.34 Mn |